personalized medicine
-
April 8, 2025
Raising AI Right: Prioritizing Humanity in Precision Medicine
With:Artificial intelligence (AI) holds promise to transform cancer research and treatment. Here, Curious Dr. George asks our very own Director of Technology, Michael Kramer, about the powerful role Cancer Commons can play in shaping the future of AI in oncology. Having lost his son, Theo, to a rare form of brain cancer—Diffuse Intrinsic Pontine Glioma (DIPG)—Kramer is deeply committed to helping others facing similar… Read more »
-
March 27, 2025
Cancer Commons: Breaking Barriers in Cancer Care
With:For more than a decade, Cancer Commons has helped patients and their care teams access the information and data they need to make informed decisions. Demand for this kind of help is only growing. Here, Curious Dr. George asks our very own Medical Director, DeLeys Brandman, MD, about her vision for expanding Cancer Commons’ services to help many more patients. In addition to her… Read more »
-
December 3, 2024
A Better Way to Keep an Eye on Glioblastoma Tumors
With:For people with glioblastoma brain tumors, it can be vital yet challenging to determine the precise size, location, and extent of the tumor. A company called Imaging Biometrics, LLC, has developed novel imaging strategies to address this issue. Here, our Curious Dr. George asks its president and CEO Michael Schmainda about these innovations. Curious Dr. George: Determining the extent of an intracranial neoplasm can be… Read more »
-
July 11, 2024
The Personalized Power of the “N-of-1” Approach
With:Randomized, controlled clinical trials with a large N—number of participants—are the recognized “gold standard” of evidence-based medicine. Even so, the results of large-N trials can only reveal population averages, and are not predictive of any individual’s response to a given treatment. On the other hand, one can consider every patient with cancer as the sole participant in their own clinical trial with an Nof1, even if the trial is not… Read more »
-
May 16, 2024
SAGE Oncotest: Entering the Next Generation of Tailored Cancer Treatment
With:For people with recurring or drug-resistant cancer, choosing the best-possible next treatment can pose a huge challenge. Our Curious Dr. George asks Chris Apfel, MD, PhD, MBA—Founder, CEO, and Board Chair of SageMedic Corp.—about his company’s solution for many of these patients. Curious Dr. George: Despite the application of curative surgical, radiation, and systemic treatments, cancer remains the “emperor of all maladies” with 600,000… Read more »
-
March 10, 2024
Protean BioDiagnostics: One Way to Access Full-Service Precision Oncology Testing
With:The use of advanced molecular testing of various cancers over the last 10-15 years has driven development of the field of precision oncology. Now, many patients with a variety of cancer types can benefit from targeted therapies. However, accessing precision testing and treatment can be a major challenge. Our Curious Dr. George asks Anthony M. Magliocco, MD, Founder and CEO of Protean BioDiagnostics, how his company… Read more »
-
August 18, 2023
Alibrex: A New Blood Test to Reveal Whether a Cancer Treatment is Working
With: Kevin Knopf, MD, MPHIn cancer treatment, time is of the essence. Our Curious Dr. George asks Kevin B. Knopf, MD, MPH, Chief Medical Officer at Cadex Genomics, how his company’s new test, Alibrex, could rapidly reveal how well a given treatment is working for a given patient. Curious Dr. George: The U.S. Food and Drug Administration has approved about 270 anti-cancer drugs. The National Comprehensive Cancer Network… Read more »
-
August 11, 2023
Common Sense Oncology: Moving Back Towards Outcomes that Matter
With:There are many ways to measure how well a particular cancer treatment works. But how much do these outcomes reflect a patient’s actual wellbeing? Our Curious Dr. George asks Christopher M. Booth, MD, FRCPC, one of the founding leaders of the new international initiative “Common Sense Oncology” (CSO), how CSO is working to improve patient outcomes. Curious Dr. George: The practice of clinical oncology… Read more »
-
June 30, 2023
PARIS Test Uses Lab-Grown Mini-Tumors to Find a Patient’s Best Treatment
With:The U.S. Food and Drug Administration (FDA) has approved hundreds of drugs for the treatment of cancer. However, some approved drugs are more effective for certain patients than others. Our curious Dr. George asks Carla Grandori, MD, PhD, Founder and CEO of SEngine Precision Medicine, about her company’s test to detect which drugs are likely to be most effective for a given patient’s solid tumor.… Read more »
-
March 16, 2023
A New Biomarker to Optimize Immunotherapy for People with Cancer
With: Scott Tomlins, MD, PhDImmunotherapy—a type of treatment that harnesses a patient’s own immune system to fight cancer—has been a “game changer” for many patients. It can be difficult, however, to predict whether or not a given person would benefit from immunotherapy, especially when it comes to drugs that target the immune system molecules PD-1 and PD-L1. Our Curious Dr. George asks Scott Tomlins, MD, PhD, Co-founder and… Read more »